Tarsus Pharmaceuticals (TARS) Insider Morrison Sells 2,954 Shares
Scott Morrison sold 2,954 shares of Tarsus Pharmaceuticals, valued at about $183,000, on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Scott Morrison sold 2,954 shares of Tarsus Pharmaceuticals, Inc. ($TARS) on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $TARS is up 2.6% after 1 week, down 4.3% after 1 month and up 9.9% to date (from the $61.95 close on Jun 12, 2026).
TARS
Tarsus Pharmaceuticals, Inc.
Key Points
- Scott Morrison sold 2,954 shares of Tarsus Pharmaceuticals on June 12, 2026, with a total value of approximately $183,000 at a share price of $61.85.
- The stock recently closed at $78.09, significantly above its 52-week low of $53.89 and below its high of $91.53.
- Analysts maintain a positive outlook on Tarsus, with a consensus rating of 'strong buy' and a mean price target of $97.67.
Get $TARS trade alerts by text
We text you when insiders, Congress or big funds trade $TARS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tarsus Pharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.
On June 12, 2026, Scott Morrison sold 2,954 shares of Tarsus Pharmaceuticals (TARS) on the NasdaqGS, valued at about $183,000 based on a share price of $61.85. This transaction sheds light on Morrison's current stance regarding his holdings in the company.
Recent Insider Activity
Morrison's sale follows a series of transactions among Tarsus insiders. On the same day, Andrew Goldberg sold 2,954 shares, while also acquiring 2,954 shares earlier in the day. Additionally, Link William Phd purchased 2,954 shares on June 12. Katherine Goodrich sold 2,954 shares just a few days later on June 15 for over $183,000, indicating active trading among the company's insiders.
How TARS Stock Has Traded
The stock of Tarsus Pharmaceuticals has seen fluctuations, recently closing at $78.09. This price is above its 52-week low of $53.89 and below its high of $91.53. With the recent sale by Morrison, the stock's performance remains a focal point for investors, especially as it trades below its 200-day moving average of $68.78.
Analysts Set New Price Targets
Analysts continue to view Tarsus positively, with several firms maintaining their ratings. On September 8, 2026, Jefferies maintained a 'Buy' rating with a price target of $105, up from $88. Oppenheimer and Mizuho also maintained their 'Outperform' ratings with targets of $100 and $98, respectively. The consensus indicates a strong buy sentiment among analysts, with a mean price target of $97.67 based on nine opinions.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals focuses on developing treatments for eye care, particularly through its product XDEMVY. The company is involved in various clinical trials aimed at addressing conditions such as demodex blepharitis and ocular rosacea. With a market cap of approximately $3.62 billion, Tarsus is positioned as a significant player in the biotechnology sector.
What's Ahead for TARS
Investors will be watching Tarsus closely as the next earnings report is scheduled for November 4, 2026. The recent insider transactions provide insights into the company's internal dynamics, although the 13F filings reflect past positions and may not indicate current holdings. Overall, the combination of insider trading and analyst ratings points to ongoing interest in Tarsus Pharmaceuticals.
Related Filing Alerts
Source: Scott Morrison's Form 4 filing on $TARS (Jun 12, 2026). Find the original filing: TARS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts